GBS Inc. (GBS)
GBS Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $0.47, down 1.58% on the session, giving a market capitalisation of $433,577. On trailing twelve-month figures it carries a trailing P/E of -0.17, a net margin of -296.8%. Its beta of 0.00 implies it has historically moved less than the broad market.
Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
GBS Inc. is most often compared with the following Healthcare names: